White House regulatory reform agenda
This article was originally published in The Gray Sheet
Office of Management and Budget is taking nominations for regs and guidance documents that impose "especially large burdens on small businesses and other small entities without an adequate benefit justification" for review. Issued March 18, 1OMB's draft report to Congress on the costs and benefits of federal regulations carries a 60-day comment period. HHS Secretary Thompson recently established a department-wide advisory panel on regulatory reform, set to meet March 20-21 in Phoenix. That panel is independently seeking comments on burdensome regulations (2"The Gray Sheet" March 18, 2002, p. 14). OMB also states that a "scientific advisory panel" including health and medical science experts will meet twice a year to evaluate Office of Information and Regulatory Affairs activities...
You may also be interested in...
Legislation shifting responsibility for the regulation of blood safety screening tests from FDA's Center for Biologics Evaluation and Research to the device center puts an enormous burden on blood organizations, according to America's Blood Centers (ABC)
Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.
Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.